REFERENCES

1. Teorell T. Kinetics of distribution of substances administered to body. *Archives of Pharmacodynamie et de Therapie* 57:205 (1937).

2. Dragstedt C.A. Oral medication with preparations for prolonged action. *J. Am. Med. Assoc.* 168:1652 (1958).

3. Hagedron H.C., Jensen B.N. and Kramp N.B. Protamine insulinate. *J. Am. Med. Assoc.* 106:177 (1936).

4. Greene J.A. and January L.E. Diabetes insipidus treated by the subcutaneous administration of a suspension of pitressin tannate in oil. *J. Am. Med. Assoc.* 115:1183 (1940).

5. Sullivan N.P., Symnes A.T., Miller H.C. and Rhodehamel H. W. A new penicillin for prolonged blood levels. *Science* 107:169 (1948).

6. Lazarus J. and Cooper J. Absorption, testing and clinical evaluation of oral prolonged action drugs. *J. Pharm. Sci.* 50:715 (1961).

7. Transdermal Therapeutic Systems. *The Pharmaceutical Strategist.* September 1996.

8. Tyle P. *Specialized Drug Delivery Systems - Manufacturing and Production Technology*, Marcel Dekker Inc., New York, 1990.

9. Robinson J.R. and Lee V.H.L. *Controlled Drug Delivery: Fundamentals and Applications.* Marcel Dekker Inc., New York, 1987.

10. Chien Y.W. *Novel Drug Delivery Systems.* Marcel Dekker Inc., New York, 1992.

11. *ORG Report* June 1996.

12. Bonn D. What prospects for hormonal contraceptives for men. *Lancet* 347:316 (1996).

13. Reynolds J.E.F. *The ExtraPharmacopoeia.* The Pharmaceutical Press, London, 1993, pp. 1170-1178.

14. Williams C.L. and Stancel G.M. Estrogen and progestins. In Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. and Gilman A.G. (eds.), *The Pharmacological Basis of Therapeutics*, McGraw Hill Co., 1996, pp. 1411-1440.

15. Ruggiero R.J. The current status of oral contraceptives. *Pharmacy Times.* January 1993, pp. 38-45.

16. Oral Contraceptives & Neoplasia. *WHO Technical Report Series No. 817.* 1991.

17. Dandiya P.C., Gurbani N.K. and Zafar Z.Y.K. *The Pharmacist Year Book.* CBS Publishers & Distributrs, New Delhi, 1996.

18. Shain R.N. and Potts M. Need for acceptability of long acting steroidal contraception. In Zatuchni G.L., Goldsmith A., Shelton J.D. and Sciarra J.J.(eds.), *Long Acting Contraceptive Delivery Systems*, Harper and Row Bros., Philadelphia, 1984, pp. 1-19.

19. Diczfalusy E. The history of steroidal contraception: What is past and what is present? In Michal F. (ed.), *Safety Requirements for Contraceptive Steroids*, Cambridge University Press, 1989, pp. 1-18.

20. Ansari A.M. and Sturtevant F.M. Intrauterine devices. In Tyle P. (ed.), *Drug Delivery Devices : Fundamentals and Applications*, Marcel Dekker Inc., New York, 1988, pp. 471-475.

21. Gabelnick H.L. and Hall P.E. Long acting methods for fertility regulation. *J. Control. Rel.* 6:387 (1987).

22. Bradin C.W. Long acting steroidal contraception and update *Int. J. Fertil.* 34:88 (1989).

23. Pharriss B.B. Uterine progesterone systems. In, Wheeter R.G., Duncan G.W. and Speidel J.J. (eds.), *Intrauterine Device : Development, Evaluation and Program Implementation*, Academic Press, 1974, pp. 203-210.

24. Scommenga A., Avila T., Luna M., Rav R. and Dmowski W.P. Fertility control by intrauterine release of progesterone. *Obstet. Gynecol.* 43:769 (1974).

25. *Physician's Desk Reference*, Medical Economics Data Production Co., Pg. 2685-2690, 1995.

26. Luukkainen T., Lahteenmaki P., Taivoness J., Levonorgestrel releasing intra-uterine device. *Ann. Med.* 22:85 (1990).

27. Anderson K., Odlind V., Rybo G., Levonorgestrel releasing and copper releasing (Nova T) IUDs during 5 Years of use. *Contraception* 49:560 (1994).

28. Luukkainen T. The levonorgestrel releasing IUD. *Br. J. Fam. Plann.* 19:221 (1993).

29. Glass R.H. and Morris J.M. Antifertility effects of an intracervical progestational device. *Biol. of Reprod.* 7:160 (1972).

30. Kurunmaki H., Toivonen J., Lahteenmaki P. and Luukkainen T. Intracervical release of levonorgestrel for contraception, *Contraception* 23:473 (1981).

31. Akinla O., Lahteenmaki P. and Jackanicz T. Intravaginal contraception with a synthetic progestin R2323. *Contraception* 14:671 (1976).

32. Greenblatt R.B. Physiologic effectiveness of progesterone vaginal suppositories. *J. Clin. Endocrinol.* **14:1564 (1954).**

33. Henzl M.R., Mishell D.R.Jr., Velasquez J.Q. and Leitch W.E. Basic studies for prolonged progestogen administration by vaginal devices. *Am. J. Obstet. Gynecol.* **117:101 (1973).**

34. Mishell D.R.Jr. and Lumkin M.E. Contraceptive effect of varying dosages of progestogen in silastic vaginal rings. *Fertil. Steril.* **21:99 (1970).**

35. Mishell D.R.Jr., Talas M., Parlow A.F. and Moyer D.L. Contraception by means of a silastic vaginal ring impregnated with medroxy progesterone acetate. *Am. J. Obstet. Gynecol.* **107:100 (1970).**

36. Mishell D.R.Jr., Lumkin M. and Stone S. Inhibition of ovulation with cyclic use of progestogen impregnated intravaginal devices. *Am. J. Obstet. Gynecol.* **113:927 (1972).**

37. Rastula K. Clinical performance of levonorgestrel releasing intracervical devices during the first year of use. *Contraception* **36:659 (1987).**

38. Kurunmaki H., Toivonen J., Lahteenmaki P. and Luukkainen T. Pituitary and ovarian function and clinical performance during the use of a Levonorgestrel releasing Intra-cervical contraceptive device. *Contraception* **29:31 (1984).**

39. Landgren B.M., Johannisson E., Xing S., Aedo A.K. and Diczfalusy E. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel. *Contraception* **32:581 (1985).**

40. Mishell D.R.Jr., Lumkin M. and Jackanicz T. Clinical studies of intravaginal rings containing norethindrone and norgestrel. *Contraception* **12:253 (1975).**

41. Mishell D.R. Jr., Moore D.E., Ray S. et al. Clinical performances and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and norgestrel. *Am. J. Obstet. Gynecol.* **130:55 (1978).**

42. Friend D.R. Transdermal delivery of levonorgestrel. *Medicinal Research Reviews.* **11:49 (1991).**

43. Chien,Y.W. et al. Transdermal dual-controlled delivery of contraceptive drugs : Formulation development in-vitro and in-vivo evaluations and clinical performance. *Pharm. Res.* **6:1000 (1989).**

44. Diczfalusy E. New developments in oral, injectable and implantable contraceptives, vaginal rings and intrauterine devices a review. *Contraception* **33:7 (1986)**

45. Croxatta H., Diaz S., Vera R., Etchart M. and Atria P. Fertility control in women with a progestogen released in microquantities from subcutaneous capsules. *Am. J. Obstet Gynecol.* 105:1135 (1969).

46. Bhatnagar S., Srivastava U.K., Takkar D., Chandra V.L., Hingorani Y. and Laumas K.R., Long term contraception by steroid releasing implants II. A preliminary report on long term contraception by a single silastic implant containing norethindrone acetate in women. *Contraception* 11:505 (1975).

47. Cuttinho E. Clinical experience with implant contraception *Contraception* 18:411 (1978).

48. Tejuja S. Use of subcutaneous silastic capsules for long term steroid contraception. *Am. J. Obstet. Gynecol.* 107:954 (1970).

49. Weiner E. and Johansson E.D.B. Contraception with d-norgestrel silastic rods: plasma levels of d-norgestrel and influence on the ovarian function. *Contraception* 14:551 (1976).

50. Nash H.A., Robertson D.N., Moo Young A.J. and Atkinson L.E. Steroid release from silastic capsules and rods. *Contraception* 18:367 (1978).

51. Jackanicz T.M., Nash H.A., Wise D.L. and Gregory J.B. Poly-lactic acid as a biodegradable carrier for contraceptive steroids. *Contraception* 8:227 (1973).

52. Gresser J.D., Wise D.L., Beck L.R., and Howes J.F. Biodegradable cylindrical implants for fertility regulation. In, Hafez E.S.E. and Van Os W.A.A (eds.), *Biodegradables and Delivery Systems for Contraception*, MTP Press, 1980, pp.83-95

53. Wise D.L., Rosenkrantz H., Gregory J.B. and Esber H.J. Long term controlled delivery of levonorgestrel in rats by means of small biodegraclable cylinders. *J. Pharm. Pharmacol.* 32:399 (1980).

54. Fotherby K., Koertswang S. and Mathrubutham M.A. A pharmacokinetic study of different doses of Depoprovera. *Contraception* 22:521 (1980).

55. Beck L.R. and Pope V.Z. Long acting injectable norethisterone contraceptive system : Review of clinical studies. *Research Frontiers in Fertility Regulation.* 3:1 (1984).

56. Hall P.E., Bialy G., Blye R.P. and Crabbe P. Development of certain levonorgestrel esters as long acting injectable contraceptives. In Zatuchni G.L., Goldsmith A., Shelton J.D. and Sciarra J.J.(eds.), *Long Acting Contraceptive Delivery Systems,* Harper and Row Bros., Philadelphia, 1984, pp. 190-200.

57. Gurny R, Tabatabay C. and Doelker E. Biodegradable polymers - Contemporary issues and new directions. *Eu. J. Hosp. Pharm.* 3:15 (1993).

58. Griffin P.D. Jones W.R. and Steyens V.C. Antifertility vaccines: current status and implications for family planning progammes. *Reproductive Health Matters.* 3:108 (1994).

59. Jones W.R., Brodley J., Jodd S.J., Denholm E.H., Ing R.M.Y., Mueller V.W., Powelll J., Griffin P.D. and Stevens V.C. Phase I clinical trial of a World Health Organization birth control vaccine. *Lancet* 331:1295 (1988).

60. Stevens V.C., Cinada B., Powell J.E., Lee A.C. and Koh S.W. Preparation and formulation of a hCG antifertility vaccine-selection of a peptide immunogen. *Am. J. of Reprod. Immunol.* 1:307 (1981).

61. Stevens V.C., Powell J.E., Lee A.E., Kaumaya P.T.R., Lewis D.H., Rickey M. and Atkins T.J. Development of a delivery system for a birth control vaccine using biodegradable microspheres. *Proceed. Intern. Symp. Control. Rel. Bioact. Materials.* 19:112 (1992).

62. Awoniyi C.A. Immunoneutralization of GnRH and subsequent treatment with testosterone silastic implants in rats, an approach toward developing a male contraceptive. *Fertil. Steril.* 58:403 (1992).

63. Rudel H.W., Martinez-Manauton J. and Maqueo-Topete M. The role of progestogens in the hormonal control of fertility. *Fertil. Steril.* 16:158 (1965).

64. Roland M. Wy 3707, a totally synthetic progestogen for contraception. *Int. J. Fertil.* 11:401 (1966).

65. Edgren R.A., Peterson D.L. and Jones R.C. Some progestational and antifertility effects of norgestrel. *Int. J. Fertil.* 11:389 (1966).

66. Edgren R.A., Peterson D.L., Jones R.C., Nagra C.L., Smith H. and Hughes G.A. Biological effects of synthetic gonanes. In Pincus G. (ed.), *Recent Progess in Hormone Research*, 22:305 (1966).

67 Kuhl H. Comparative pharmacology of newer progestogens. *Drugs.* 51:188 (1996).

68. Edgren R.A., Smith H., Peterson D.L., and Carter D.L. The biological effects of a series of 13β - substituted gonanes related to norethisterone. (17α- ethynyl- 19-nortestosterone), *Steroids* 2:319 (1963).

69. Edgren R.A., Jones R.C. and Peterson D.L. A biological classification of progestational agents. *Fertil. Steril.* 18:238 (1967).

70. Edgren R.A, Smith H., Hughes G.A., Smith L.L. and Greenspan G. Biological effects of racemic and resolved 13ß-ethyl- 4-gonen- 3 ones. *Steroids* 2:731 (1963).

71. *British Pharmacopoeia* 1993.

72. *U.S.Pharmacopoeia XXIII* 1995.

73. Cullen L.F. and Sopirak A.M. Norgestrel. In Florey K.(Ed.), *Analytical Profiles of Drug Substances, vol.4*, Academic press, 1975, pp. 294-318.

74. Battle C.W. and Corbin A. The differential effects of diestrous progestogen administration on proestrous gonadotropin levels. *Endocrinology* 97:885 (1975).

75. Hori T., Kata G. and Miyuke T. Acute effects of ovarian steroids upon follicular growth in the cycling rat. *Endocrinology, Japan*, 20:475 (1973).

76. Briggs M. Biochemical effects of oral contraceptives. *Adv. Steroid Biochem. Pharmacol.* 5:66 (1976).

77. Chan L. and O'Malley B.W. Mechanism of action of sex steroid hormones. *N. Engl. J. Med.* 294:1322 (1976).

78. O'Roark H.C., Lock F.R., Smith F.J.H. and Burt R.L. Preliminary clinical study of wy 3707 with ethinyl estradiol as an oral contraceptive. *Int. J. Fertil.* 11:405 (1966).

79. Ronald M., Clyman M.J., Decker A. and Ober N.B. Control of conception with a new progestational steroid. *Obstet. Gynecol.* 27:222 (1966).

80. Spona J., Schneider W.H.F., Bieglmayer C.H., Schroeder R. and Pirker R. Ovulation inhibition with different doses of levonorgestrel and other progestogens: Clinical and experimental investigations. *Acta Obstet. Gynecol. Scand. Suppl.* 88:7 (1979).

81. Henzel M.R. Contraceptive hormones and their clinical use. In Yen S.S.C. and Jotte R.B. (eds.), *Reproductive Endocrinology*, W.B.Saunders & Co., 1991, pp. 807-829.

82. Weiner E., Johansson E.D.B. and Wide L. Inhibition of the positive feedback of oestradiol during treatment with subcutaneous implants of of norgestrel. *Contraception* 13:287 (1976).

83. Naqvi R.H., Mitra S.B., Saxena I.F. and Lindberg M.C. Pharmacokinetics of levonorgestrel in the rat. *Contraception* 30:81 (1984).

84. Naqvi R.H., Mitra S.B. and Lindberg M.C. Effect of dose on the pharmacokinetics of levonorgestrel in the rat during the rapid eliminiation phase following subcutaneous adminstration. *Contraception* 30:599 (1984).

85. Nair K.M., Sivakumar B. and Rao B.S.N. The rabbit as an animal model to study pharmacokinetics of levonorgestrel in women. *Contraception* 23:89 (1981).

86. Nair K.M., Sivakumar B. and Rao B.S.N. Effect of food restriction on pharmacokinetics of levonorgestrel in rabbits. *Contraception* 23:549 (1981).

87. Dusterberg B. Plasma levels of levonorgestrel, gestodone, norethisterone and cyproterone acetate on single dose subcutaneous administration in oily solution in the rat, beagle and rhesus monkey. *Steroids* 22:43 (1983).

88. Dusterberg B., Humpel M. and Speck U. Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys. *Contraception* 24:673 (1981).

89. Dusterberg B. and Beier S. Plasma levels and progestational activity of levonorgestrel after repeated intravenous and subcutaneous administration in the beagle bitch. *Contraception* 29:345 (1984).

90. Humpel M., Wendt H., Pommerenke G. and Speck U. Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women. *Contraception* 17:207 (1978).

91. Victor A., Weiner E. and Johansson E.D.B. Sex hormone binding globulin: The carrier protein for d-norgestrel. *J. Clin. Endocrinol. Metab.* 43:244 (1976).

92. Littleton P., Fotherby K. and Dennis K. J. Metabolism of ^{14}C norgestrel in man. *J. Endocrinol.* 42:591 (1968)

93. Sisenwine S.F., Kimmel H.B., Liu A.L. and Ruelius H.W. Stereoselective biotransformations of dl-norgestrel and its enantioers in the African green monkey. *Drug Metab. Dispos.* 2:65 (1974).

94. Sisenwine S.F., Kimmel H.B., Liu A.L. and Ruelius H.W. The metabolic disposition of norgestrel in female rhesus monkeys. *Drug Metab. Dispos.* 7:1 (1979).

95. Sisenwine S.F., Kimmel H.B., Liu A.L. and Ruelius H.W. Excretion and stereoselective biotransformations of dl, d- and l-norgestrel in women. *Drug Metab. Dispos.* 3:180 (1975).

96. Warren R.J. and Fotherby K. Metabolism of D- and L-norgestrel in humans. *Arzneim. Forsch.* 25:964 (1975).

97. Sisenwine S.F., Kimmel H.B., Liu A.L. and Ruelius H.W. The presence of dl, d and l- norgestrel and their metabolites in the plasma of women. *Contraception* 12:339 (1975).

98. Nilsson C.G. *Am. J. Obstet. Gynec.* 129:178 (1977).

99. Back D.J., Grimmer S.F.M., Rogers, S., Sterensong P.J. and Orme M.L'E. Comparative pharmacokinetics of levonorgestrel and ethynil estradiol following i.v., oral and vaginal administration. *Contraception* 36:471 (1987).

100. Grimmer S.F.M., Back, D.J., Orme, M.L'E., Cowie A., Gilmore I. and Tjia J. The bioavailability of ethynil estradiol and levonorgestrel in patients with an ileostomy. *Contraception* 33:51 (1986).

101. Back. D.J., Killick, S.R., Stevenson, P.J., Shenoy N., Elstein M. and Cohen M. The relative bioavailability of levonorgestrel and ethinyl estradiol when administered in tablet and capsule form. *Contraception* 36:321 (1987).

102. Weiner E., Victor A. and Johansson E.D.B. Plasma levels of d-norgestrel after oral administration. *Contraception* 14:563 (1976).

103. Nilsson C.G., Lahteenmaki P., Robertson D.N. and Luukkainen T. Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated IUD. *Acta Endocrinol.* 83:380 (1980).

104. Landgren B.M., Johannisson E., Masironi B. and Diczfalusy E. Pharmacokinetic and pharmacodynamic investigtions with vaginal devices releasing levonorgestrel at a constant, near zero order rate. *Contraception* 26:567 (1982).

105. Rastula K., Toivonen J., Lahteenmaki P. and Luukkainen T. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel releasing intracervical device. *Contraception* 39:195 (1989).

106. Landgren B.M., Aedo A.R., Cekan S.I. and Diczfalusy E. Pharmacokinetic studies with a vaginal delivery system releasing levonorgestrel at a near zero order rate for one year. *Contraception* 33:473 (1986).

107. Lancaster M.C. Long term results of toxicological studies with norgestrel combinations. *Excerpta Med. Int. Congr. Ser.*, 1974 pp. 344.

108. Frost O. Tracheo-oesophageal fistula associated with hormonal contraception during pregnancy. *Br. Med. J.* 2:978 (1976).

109. Otten J. Hepatoblastoma in an infant after contraceptive intake during pregnancy. *N. Engl. J. Med.* 297:222 (1977).

110. Viegas O.A.C. The effects of norplant on clinical chemistry in Singaporean acceptors after 1 year of use - I.: haemostatic changes. *Contraception* 38:313 (1988).

111. Singh K. Two year follow up of changes in clinical chemistry in Singaporean Norplant 2 rod acceptors : haemostatic changes. *Contraception* 39:155 (1988).

112. Affandi B., Santoso S.S.I., Hadisaputra W., Moeloek F.A. Prihartono J., Lubis F. and Sami R.S. Five year experience with Norplant. *Contraception* 36:417 (1987).

113. Anonymous. Facts about an implantable contraception. *Bulletin of the W.H.O.* 63:485 (1985).

114 Graham R.E., Williams P.A. and Kenner C.T. Detection of decomposition and analytical interference in pharmaceutical preparations containing corticosteroids. *J. Pharm. Sci.* 59:1152 (1970).

115 Umberger E.J. Isonicotinoyl hydrazide as a reagent for determination of 3-keto steroids : Determination of progesterone and testosterone propionate in oil solutions. *Anal. Chem.* 27:768 (1955).

116 John Y.P. Colorimetric determination of progestational steroids in contraceptive tablets. *J. Ass. Offic. Anal. Chem.* 53:831 (1970).

117 Smith R.V., Hassall T.H. and Liv S.C. Colorimetric analysis of norethindrone, norethindrone acetate and norgestrel in oral contraceptives. *J. Ass. Offic. Anal. Chem.* 53:1089 (1970).

118 Short P.M. and Rhodes C.T. Automated colorimetric assay of norgestrel.*Steroids* 16:217 (1970).

119 Short P.M. and Rhodes, C.T. Scope of automation in pharmaceutical analysis.*Can. J. Pharm. Sci.* 8:26 (1973).

120 Cullen L.F., Rutgers J.G., Lucchesi P.A. and Papariello G.J. Fluorometric determination of norgestrel and structurally related steroids. *J. Pharm. Sci.* 57:1857 (1968).

121. Carignan G., Lodge B.A. and Skakum W. General reversed phase high performance liquid chromatography procedure for the analysis of oral contraception formulations. *J. Chromatogr.* 315:470 (1984).

122. Iohan F., Jackanicz T. and Monder C. Measurement of ethynil estradiol and levonorgestrel incorporated into sustained release contraceptive formulations. *Contraception* 32:571 (1985).

123. Kanluam T., Masironi B. and Cekan, S.Z. On the validity of levonorgestrel radioimmunoassay. *Clinica Chimica Acta.* 109:169 (1981).

124. Stanczyk F.Z., Hiroi M., Goebelsmann U., Brenner P.F. Lumkin M.E. and Mishell D.R. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration. *Contraception* 12:279 (1975).

125. Higuchi T. and Kuramoto S. Study of possible complex formation between macromolecules and certain pharmaceuticals I. *J. Am. Pharm. Assoc. (Sci.Edn.)* 43:393 (1954).

126. Thompson R.E. Sustained release of parenteral drugs. *Bull. Parent. Drug Assoc.* 14:6 (1960).

127. Thompson R.E. and Hecht R.A. Studies on a long action vitamin B_{12} preparation. *Am. J. Clin. Nutr.* 7:311 (1959).

128. Tice T.R. and Tabibi E.S. Parenteral drug delivery In, Kydonieus A. (ed.), Treatise on Controlled Drug Delivery - Fundamentals, Optimization and Application, Marcel Dekker Inc., New York, 1991, pp.319-329.

129. Davis S.S., Illum L. and Burgess D. Microspheres as controlled-release systems for parenteral and nasal administration. In, Lee P.I. and Good W.H. (eds.), *Controlled Release Technology - Pharmaceutical Applications*, American Chemical Society, New York, 1987, pp.201-209.

130. Krowczynski L. *Extended - Release Dosage Forms.* CRC press Inc., Boca Raton, Florida, 1987.

131. Sanders L.M., McRae G.I. and Vitale K.M. Controlled delivery of an LHRH analogue from biodegradable injectable microspheres. *J. Control. Rel.* 2:182 (1986).

132. Pitts C.G., Marks J.A. and Schindler A. Biodegradable drug delivery systems based on aliphatic polyesters : applications to contraceptives and narcotic antagonists. In Baker R. (ed.), *Controlled Release of Bioactive Materials*, Academic Press, New York, 1980, pp.19-43.

133. Woodland J.H.R., Yolles D.A. and Blake M. Long-acting delivery systems for narcotic antagonists I. *J. Med. Chem.* 16:897 (1973).

134. Masan N., Thies C. and Cicero J.F. In-vivo and in-vitro evaluation of a microcapsulated narcotic antagonist. *J. Pharm. Sci.* 66:847 (1976).

135. Wise D.L., McCormick G.I. and Willet G.P. Sustained release of sulphadiazine. *J. Pharm. Pharmacol.* 30:686 (1978).

136. Tsakala M., Gillard J. and Roland M. Pyrimethamine sustained release systems based on bioresorbable polyesters for chemoprophylaxis of rodent malaria. *J. Control. Rel.* 5:233 (1988).

137. Florence A.T., Jenkins A.W. and Loveless A.H. Approaches to the formulation of a long acting I.M. injection. *J. Pharm. Pharmacol. Suppl.* **25:121P (1973).**

138. Scheu J.D., Sperandion G.I. and Shaw S.M. Use of microcapsules as time-release parenteral dosage form : Application as radiopharmaceutical imaging agent. *J. Pharm. Sci.* **66:172 (1977).**

139. Nixon J.R. In-vitro and in-vivo release of microencapsulated chlorothiazide. *J. Pharm. Sci.* **70:376 (1981).**

140. Singh M. and Ravni L.J. Parenteral emulsions as drug carrier systems. *J. Parenter. Sci. Technol.* **40:34 (1986).**

141. Rao L.S. Liposomal dosage form development - some practical considerations. *J. Parenter Sci. Technol.* **37:71 (1983).**

142. Juliano R.L. Multiparticulate Drug carriers : Liposomes, Microspheres and cells In Robinson J.R. & Lee V.H.L. (eds.), *Controlled Drug Delivery - Fundamentals and Concepts*, Marcel Dekker Inc., New York, 1987. pp.568.

143. Desai S.J., Simonelli A.P. and Higuchi W.I. Investigation of factors influencing release of solid drug dispersed in inert matrices. *J. Pharm. Sci.* **54:1459 (1965).**

144. Folkman J. and Long D.M. The use of silicone rubber as a carrier for prolonged drug therapy. *J. Surg. Res.* **4:139 (1964).**

145. Waitz J.A., Olszewski B.J. and Thompson P.E. Dialysis studies in rats on long-acting antimalarial Cl-105. *Science* **141:723 (1968).**

146. Tatum H.J. Fertility control and acceptability in women of contraceptive steroids released in micro quantities from subcutaneous silastic capsules. *Contraception* **1:253 (1970).**

147. Baker R.W. and Lonsdale H.K. Controlled release mechanisms and rates. In, Tanquary A.C. and Lacey R.E. (eds.), Controlled Release of Biologically Active Agents. Plenum press, New York, 1974, 47:15.

148. Rogers C.E. Solubility and diffusivity. In, Fox D., Labes M.M. and Weissberger A. (eds.), Physics and Chemistry of the Orgainc Solid State, Interscience, New York, 1965, 2:510.

149. Crank J. and Park G.S. *Diffusion in Polymers*, Academic Press, London, 1968.

150. Langer R.S. and Peppas N.A. Present and future applications of biomaterials in controlled drug delivery. *Biomaterials* **2:201 (1981).**

151. Heller J. Controlled release of biologically active compounds from bioerodible polymers. *Biomaterials* **1:51 (1980).**

152. Benagiano G. and Gabelnick H. Biodegradable systems for the sustained release of fertility regulating agents. *J. Steroid Biochem.* **11:449 (1979).**

153. Pitt C.G. and Schindler A. The design of controlled drug delivery systems based on biodegradable polymers. In, Hafez E.S.E. and Van Os W.A.A. (eds.), *Biodegradables and Delivery Systems for Contraception*, MTP Press Ltd., Lancaster, England, 1980, pp.17-47.

154. Graham N.B. Polymeric inserts and implants for the controlled release of drugs. *Br. Polym. J.* **10:260 (1978).**

155. Kim S.W., Petersen R.V. and Feijen J. Polymeric drug delivery systems in Ariens E.J. (eds.), *Drug Design*, Academic press, New York, 1980, chap.5.

156. Schindler A., Jeffcoat R., Kimmel G.L., Pitt C.G., Wall M.E. and Zweidinger R. Biodegradable polymers for sustained drug delivery. In, Pearce E.M. and Schaefgen J.R. (eds.), *Contemporary Topics in Polymer Science*, vol.2, Plenum press, New York, 1977, pp.251-289.

157. Bogdansky S. Natural polymers as drug delivery systems. In, Chasin M. and Langer R. (eds.), *Biodegradable Polymers as Drug Delivery Systems*, Marcel Dekker, New York, 1990, pp.231.

158. Skiens W.E., Burton F.G. and Duncan G.W. Biodegradable delivery systems. In, Hafez E.S.E. and Van Os W.A.A. (eds.), *Biodegradables and Delivery Systems for Contraception*, MTP Press Ltd., Lancaster, England, 1980, pp.3-16.

159. Heller J., Penhale D.W.H., Fritzinger B.K., Rose J.E. and Helwing R.F. Controlled release of contraceptive steroids from biodegradable poly (ortho esters). *Contracept. Delivery Systems.* **4:43 (1983).**

160. Heller J., Penhale D.W.H., Fritzinger B.K. and Ng S. Y. In-vitro and in-vivo release of levonorgestrel from poly-(ortho-esters), II. Crosslinked polymers. *J. Control. Rel.* **1:233 (1985).**

161. Heller J., Ng S.Y., Penhale D.W.H., Fritzinger B.K., Sanders L.M., Burns R.A., Gaynon, M.G. and Bhosale S.S. The use of poly (ortho-esters) for the controlled release of 5-fluorouracil and a LHRH analogue. *J. Control. Rel.* **6:217 (1987).**

162. Leong K.W., Brott B.C. and Langer R. Bioerodible poly anhydrides as drug-carrier matrices 1- Characterization, degradation and release charcteristics. *J. Biomed. Mater. Res.* **19:941 (1985).**

163. Mathiowitz E. and Langer R. Poly anhydride microspheres as drug carriers - I. Hot-melt microencapsulation. *J. Control. Rel.* **5:13 (1987).**

164. Bindschaedler C., Leong K.W., Mathiowitz E. and Langer R. Polyanhydride microsphere formulation by solvent extraction. *J. Pharm. Sci.* **77:696 (1988).**

165. Sidman K.R., Schwope A.D., Steber W.D., Rudolph S.E. and Poulin S.B. Biodegradable, implantable sustained release

163. Mathiowitz E. and Langer R. Poly anhydride microspheres as drug carriers - I. Hot-melt microencapsulation. *J. Control. Rel.* 5:13 (1987).

164. Bindschaedler C., Leong K.W., Mathiowitz E. and Langer R. Polyanhydride microsphere formulation by solvent extraction. *J. Pharm. Sci.* 77:696 (1988).

165. Sidman K.R., Schwope A.D., Steber W.D., Rudolph S.E. and Poulin S.B. Biodegradable, implantable sustained release systems based on glutamic acid copolymers. *J. Membr. Sci.* 7:277 (1980).

166. Kohn J. and Langer R. A new approach to the development of bioerodible polymers for controlled release applications empolying naturally occuring amino acids. *Proceed. of the ACS Division of Polymeric Materials, Science and Engineering.* 51:119 (1984).

167. Courveur P. and Vouthier C. Polyalkyl cyanoacrylate nanoparticles as drug carrier present state and perspectives. *J. Control. Rel.* 17:187 (1991).

168. Couvreur P., Kante B., Gristain L., Roland M. and Speiser P. Toxicity of polyalkyl cyanoacrylate nanoparticles-II. Doxorubicin loaded nanoparticles. *J. Pharm. Sci.* 71:790 (1982).

169. Gralieman C.W.J., De Visser A.C., Wolke J.Q.C., Klein C.P.A.T., van der Goot H. and Timmerman H. Studies on a bioerodible drug carrier system based on a polyphosphazene. *J. Control. Rel.* 3:143 (1986); 4:119 (1986) and 4:133 (1986).

170. De Luca P.P., Mehta R.C., Hausberger A.G., and Thanoo B.C., Biodegradable Polyesters for Drug and Polypeptide Delivery. In, *Polymeric Delivery Systems*, ACS symp. Ser., Vol 520, 1993, pp. 53-70.

171. Frazza E.J. and Schmitt E.E. A new absorbable suture. *J. Biomed. Mater. Res. Symp.* 1:43 (1971).

172. Brady J.M., Cutright D.E., Miller R.A. and Battistone G.C. Resorption rate, route of elimination, and ultrastructure of the implant site of polylactic acid in the abdominal wall of the rat. *J. Biomed. Mater. Res.* 7:155 (1973).

173. Du Pont de Nemours and Co. *U.S.Patent 3,773,919.* 1969.

174. Dunn R.L., Lewis D.H. and Goodson J.M. Monolithic fibers for controlled delivery of tetracycline. *Proceed. Int. Symp. Control. Rel. Bioact. Mater.* 9:157 (1982).

175. Eenink M.J.D., Feijen J., Oligslonger J., Albers J.H.M., Rieke J.C. and Griedonus P.J. Biodegradable hollow fibers for the controlled release of hormones. *J. Control. Rel.* 6:225 (1987).

176. Spenlehauer G., Vert M., Benoit J.P., Chabot F. and Veillard M. Biodegradable cisplatin microspheres prepared by the solvent evaporation method, Morphology and release characteristics. *J. Control. Rel.* 7:217 (1988).

177. Beck L.R. and Pope V.Z. Controlled release delivery systems for hormones. *Drugs* 270:528 (1984).

178. Gilding G.K., Reed A.M., Biodegradable polymer for use in surgery, poly (glycolic)/poly(lactic acid) homo-and copolymers : 1. *Polymer* 20:1459 (1979).

179. Kulkarni R.K., Moore E.G., Hegyelli A.F. and Lednard F. *J. Biomed. Mater. Res.* 5:169 (1971).

180. Fukuzaki H., Yoshida M., Asano M., Kumakura M., Mashimo T., Yuasa H., Imai K. and Yamanaka H. In-vivo characteristics of high molecular weight copoly (L-lactide/glycolide) with S- type degradation pattern for application in drug delivery systems. *Biomaterials* 12:433 (1991).

181. Chasin M., Domb A., Ron E., Mathiowitz E., Leong K. Laurencin C., Brem H., Grassman S. and Langer R. Polyanhydrides as drug delivery systems. In, Chasin M. and Langer R. (eds.), *Biodegradable Polymers as Drug Delivery Systems*, Marcel Dekker, New York, 1990, pp.43-70.

182. Miller R.A., Brady J.M. and Cutright D.E. Degradation rates of oral resorbable implants (polylactates and polyglycolates), Rate modification with changes in PLA/PGA copolymer ratios. *J. Biomed. Mater. Res.* 11:711 (1977).

183. Pitt C.G., Gratzel M.M., Kimmel G.L., Surles J. and Schindler A. Aliphatic polyesters 2. The degradation of poly (D.L.lactide), Poly (ϵ-caprolactone) and their copolymer in vivo. *Biomaterials* 2:215 (1981).

184. Cutright D.E., Bienvenido P., Beasly J.D. and Larsen W.J. Degradation rates of polymers and copolymers of polylactic and polyglycolic acids. *Oral surg. Oral Med. Oral Pathol.* 37:142 (1974).

185. Beck L.R. and Tice T.R. Poly (lactic acid) and poly (lactic acid-co-glycolic Acid) contraceptive Delivery Systems. In, Mishell D.R. (ed.), *Long Acting steroid Contraception*, Raven Press Books Ltd, New York, 1983, pp.175-199.

186. Cowsar D.R. and Tice T.R. Poly (lactide-co-glycolide) Microcapsules for controlled release of steroids. *Methods in Enzymology* 112:101 (1985).

187. Potts J.E., Clendinning R.A., Ackart W.B. and Niegisch W.D. Biodegradability of Synthetic polymers. *Polym. Sci. Technol.* 3:61 (1973).

188. Crescenzi V., Manzini G., Calzalari G. and Borri C., Thermodynamics of fusion of poly-β-propiolactone and poly-ε-caprolactone, comparative analysis of the melting of aliphatic polylactone and polyester chains. *Eur. Polym. J.* **8:449 (1972).**

189. Pitt C.G., Jeffcoat A.R., Zweidinger R.A. and Schindler A. Sustained drug delivery systems.-I. The permeability of poly (ε-caprolactone), poly (DL-lactic acid), and their copolymers. *J. Biomed. Mater. Res.* **13:497 (1979).**

190. Pitt C.G., Gratol M.M., Kimmel G.L., Surtes J. and Schindler A. Aliphatic polyesters.- II. The degradation of poly (DL-lactide), poly (ε - caprolactone) and their copolymers in-vivo. *Biomaterials* **2:215 (1981).**

191. Pitt C.G. and Schindler A. Biodegradation of polymers. In, Bruck S. D. (eds.), *Controlled Drug Delivery, Vol.1,* CRC Press, Boca Raton, 1983, pg.53-80.

192. Pitt C.G., Chasalow F.I., Hibionada Y.M., Klimas D.M. and Schindler A. Aliphatic polyesters I. The degradation of poly (ε caprolactone) in-vivo. *J. Appl. Polym. Sci.* **26:3779 (1981).**

193. Pitt C.G. and Gu Z.W., Modification of the rates of chain cleavage of poly (ε caprolactone) and related polyesters in the solid state. *J. Control. Rel.* **4:283 (1987).**

194. Chang R.K., Price J.C. and Whitworth C.W. Enhancement of dissolution rate by incorporation into a water insoluble polymer, polycaprolactone. *Drug Dev. Ind. Pharm.* **13:249 (1987).**

195. Pitt C.G., Cho Y., Hendren R.W., Holloman M. and Schindler A. Manipulation of the permeability and degradablity of polymers. *Proceed. 14th Int. Symp. Control. Rel. Bioactive Materials.* **11:108 (1987).**

196. Chang R.K., Price J. and Whitworth C.W. Control of drug release rate by use of mixtures of polycaprolactone and cellulose acetate butyrate polymers. *Drug Delivery Ind.Pharm.* **13:1119 (1987).**

197. Research Triangle Institute Report to NICHD, NIH, August, 1977.

198. Wade C.W.R., Hegyelli A.F. and Kulkarni R.K. Standards for in-vitro and in-vivo comparison and qualification of bioabsorbable polymers. *J. Test Eval.* **5:397 (1977).**

199. Ory S.J., Hammond C.B., Yancy S.G., Pitt C.G. and Hendren R.W. A clinical trial of a biodegradable contraceptive capsule containing levonorgestrel. *Am. J. Obstet. Gynecol.* **145:600 (1983).**

200. Fergusson J.H. Sterilization of controlled-release systems. In, Hsieh D.S.T. (ed.), *Controlled Release systems : Fabrication Technology, Vol.II,* CRC Press Inc., Boca Raton, Florida 1988, pg.163-178.

201. Gopal N.G.S. Radiation sterilization of pharmaceuticals and polymers. *Radiat. Phys. Chem.* **12:35 (1978).**

202. White J.D. and Bradley T.J. Residual EO in gas sterilised medical-grade silicones. *J. Pharm. Sci.* **62:1634 (1973).**

203. Chu C.C. and williams D.T. The effect of gamma irradiation on the enzymatic degradation of polyglycolic acid and absorbable sutures. *J. Biomed. Mater. Res.* **17:1029 (1983).**

204. Tice T.R., Lewis D.H., Dunn R.L., Meyers W.E., Casper R.A. and Cowsar D.R. Biodegradation of microcapsules and biomedical devices prepared with resorbable polyester. *Proceed. Int. Symp. Control. Rel. Bioact. Mater.* **9:21 (1982).**

205. Gupta M.C. and Deshmukh V.G. Radiation effects on poly (lactic acid) *Polymer* **24:827 (1983).**

206. Kalkwart D.R., Sikov M.R. and Smith L. Release of progesterone from polyethylene devices in-vitro and in experimental animals. *Contraception* **6:423 (1972).**

207. Chien Y.W., Lambert H.J. and Grant D.E. Controlled drug release from polymeric devices I. Technique for rapid in-vitro release studies. *J. Pharm Sci.* **63:364 (1974).**

208. Mathowitz E. and Langer R. Polyanhydride microcapsules as drug carriers. Hot melt microencapsulation. *J. Control. Rel.* **5:13 (1987).**

209. Bischoff, F., Organic polymer biocompatiblity and toxicology. *Clin. Chem.* **18:869 (1972).**

210. Langer R., Brem H. and Tapper D. Biocompatiblity of polymeric delivery systems for macromolecules. *J. Biomed. Mater. Res.* **15:267 (1981).**

211. Adams R.O., Denny-Brown D. and Pearson C.M. *Diseases of Muscles*, Harper & Row Bros., New York, 1972.

212. Goldberg L., Baker C.S.B. and Smith J.P. The effects of subcutaneous aluminium dextran in mice and rats. *J. Path. Bact.* **85:435 (1963).**

213. Dumphy J.E. and Udupa K.N. Chemical and histochemical sequences in normal wound healing. *N. Engl. J. Med.* **253:847 (1955).**

214. Buckles R.G. Biomaterials for drug delivery systems. *J. Biomed. Mat. Res.* **17:109 (1983).**

215. *The United States Pharmacepoeia XXIII*, 1990.

216. Floy B.J., Viser G.C. and Sanders L.M. Design of biodegradable polymer systems for controlled release of bioactive agents. In, *Polymeric Delivery Systems*, ACS Symp. Ser., Vol. 520, 1993, pp.155-167.

217. *ASTM Standards on Chromatography*, An American National Standard, 1981, pp. 504-522.

218. Ford J.L. and Timmins P. *Pharmaceutical Thermal Analysis Techniques and Applications*, Ellis Horwood Ltd., 1989.

219. Gilding D.K., Reed A.M. and Askil I.N. Calibration in gel permeation chromatography: primary, universal and emperical methods. *Polymer* 22:505 (1981).

220. Hausberger A.G. and De luca P.P. Characterisation of biodegradable poly (D,L-lactide-co-glycolide) polymers and microspheres. *J. Pharm. Biomed. Anal.* 13:747 (1995).

221. Lalla J.K. and Chugh N.N. Biodegradable polymer polylactic acid Part I: synthesis evaluation and structural elucidation. *Indian Drugs* 27:516 (1990).

222. Lalla J.K., Sapna K. and Poddar S.S. Synthesis and evaluation of poly (DL-lactic acid). *Indian Drugs* 30:430 (1993).

223. Feng X.D., Song C.X. and Chen W.Y. Synthesis and evaluation of biodegradable block copolymers of ϵ caprolactone and DL-lactide. *J. Polym. Sci.* 21:593 (1983).

224. Jalil R. and Nixon J.R. Microencapsulation using poly (DL-lactic acid) IV : Effect of storage on microcapsules characteristics. *J. Microencapsulation* 7:375 (1990).

225. Aso Y., Yoshioka S. and Terao T. Effects of storage on the physicochemical properties and release characteristics of progesterone loaded poly (l-lactide) microspheres. *Int. J. Pharm.* 93:153 (1993).

226. Aso Y., Yoshioka S. and Terao J., Effects of storage on the physicochemical properties and release characteristics of progesterone loaded poly (l-lactide) microspheres II. *Int. J. Pharm.* 115:133 (1995).

227. Pharmacopoeia of Indian, vol.II, 3rd edn., Govt.of India, Ministry of Health and Family Welfare, 1985, pp. A108-A112.

228. Hausberger A.G., Kenley R.A. and Deluca P.P. Gamma irradiaton effects on molecular weight and in-vitro degradation of poly (DL-Lactide-co-glycolide) microparticles. *Pharm. Res.* 12: 851 (1995).

229. Schroeder H., Simmons G.H. and Deluca P.P. Distribution of radiolabeled subvisible microspheres after i.v. administration to beagle dogs. *J. Pharm. Sci.* 67:504 (1978).

230. Aso Y., Yeshioka S. and Kojima S. Drug release from Poly (DL-lactide) micropheres controlled by τ-irradiation. *J. Control. Rel.* 37:263 (1995).

231. Tice T. R. and Lewis D. H. *U.S.Patent No. 4,389,330.* 1983.

232. Li W.I, Anderson K.W., Mehta R.C. and Deluca P.P. Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microsphers prepared by solvent extraction/evaporation method. *J. Control. Rel.* 37:199 (1995).

233. Li W.I., Anderson K.W. and Deluca P.P. Kinetic and thermodynamic modeling of the formation of polymeric for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method. *J. Control. Rel.* 37:215 (1995).

234. Arshady R. Preparation of biodegradable microspheres and microcapsules : 2 polylactides and related polyesters *J. Control. Rel.* 17:1 (1991).

235. Benoit J.P., Gomez J.L., Alonso M.J. and Juliene M.C. Preparation of poly (D,L-lactide/glycolide) nanoparticles of controlled particle size distribution : application of experimental designs. *Drug Dev. Ind. Pharm.* 18:1063 (1992).

236. Conti B., Genta I., Modena T. and Pavanetto F. Investigation on process parameters involved in polylactide-co-glycolide microspheres preparation. *Drug Dev. Ind. Pharm.* 21: 615 (1995).

237. Moes A.J. and Sansdrap. P. Influence of manufacturing parameters on the size characteristics and the release profiles of nifedepine from poly (DL-lactide-co-glyclolide) microspheres *Int. J. Pharm.* 98:157 (1993).

238. Beck L.R., Cowsar D.R. and Tice T.R. Poly (DL-lactide-co-glycolide)/Norethisterone microcapsules : An injectable biodegradable contraceptive. *Biol. of Reprod.* 28:186 (1983).

239. Washington C. Drug release from microparticulate sysytems. In, Benita S. (ed.), *Microencapsulation : Methods and Industrial Applications*, Marcel Dekker Inc., New York, 1996, pp. 155-182.

240. Banakar U.V. *Pharmaceutical Dissolution Testing*, Marcel Dekker Inc., New York, 1992.

241. Beck L.R., Pope V.Z., Cowsar D.R., Lewis D.H. and Tice T.R. Evaluation of a new three month injectable contraceptive microsphere system in primates (Baboon) *Contracept. Delivery System.* 1:79 (1980).

242. Gu Z-W., Ye W-P. Yang J-U., Li Y-X., Chen X-I., Zhong G-W. and Feng X-D. Biodegradable block copolymer matrices for long acting contraceptives with constant release. *J. Control. Rel.* 22:3 (1992).

243. Parikh B.V., Upadrashta S.M., Neau S.H. and Nueesle N.O. Oestrone loaded poly (1-lactic acid) microspheres : Preparation, evaluation and in-vitro release kinetics. *J. Microencapsulation* 10:141 (1993).

244. Gao Z.H., Shukla A.J., Johnson J.R. and Crowley W.R. Controlled release of contraceptive steroid from biodegradable and injectable gel formulations : in-vitro evaluation. *Pharm. Res.* 12:857 (1995).

245. Gangrade N and Price J.C. poly (hydroxy butyrate-hydroxy valerate) microspheres containing progesterone : preparation, morphology and release properties. *J. Microencapsulation* 8:185 (1991).

246. Guy R.H., Hadgraft J., Kellaway I.W. and Taylor M.J. Calculations of drug release rates from spherical particles, *Int. J. Pharm.* 11:199 (1982).

247. Forni F., Coppi G., Vandelli M.A. and Bernabei M.T. An interpretation of the diffusion type mechanism of drug release from microcapsules *Int. J. Pharm.* 60:83 (1990).

248. Carmichael G.R., Shah S.A. and Parrott E.L. General model for dissolution rates of n-component, nondisintegrating spheres. *J. Pharm. Sci.* 70:1331 (1981).

249. Wise D.L. Poly(Lactic/glycolic acid) biodegradable drug-polymer matrix systems. *Methods in Enzymology* 112:436 (1985).

250. Tice T.R. and Cowsar D.R. Biodegradable controlled release parenteral systems, *Pharmaceutical Technology*, pp. 26-36, November, 1984.

251. Dubernet C., Benoit J.P., Couarraze G. and Duchene D. Microencapsulation of nitrofurantoin in poly-ε-caprolactone: tabletting and in-vitro release studies. *Int. J. Pharm.* 35:145 (1987).

252. Akers M.J., Fites A.L. and Robinson R.L. Formulation, Design and Development of parenteral suspensions *J. Parenter. Sci. Technol.* 41:88 (1987).

253. Blackshear P. J. Control of blood glucose in experimental diabetes by means of a totally implantable insulin infusion device. *Diabetes* 28:634 (1979)

254. Danckwerts M. and Fassihi A. Implantable controlled release drug delivery systems: A review. *Drug Dev. Ind. Pharm.* 17:1465 (1991).

255. Coutinho E.M. Results of a user satisfaction study carried out in women using Uniplant contaceptive implant. *Contraception* 54:313 (1996).

256. Gabelnick H.L. Biodegradable implants : Alternative approaches. In, Mishell D.R. (ed.), *Long Acting Steroid Contraception*, Raven press, New York, 1981, pp. 149-173.

257. Gangrade N. and Price J.C. Properties of implantable pellets prepared from a biodegradable polyester. *Drug Dev. Ind. Pharm.* 18:1633 (1992).

258. Yashioka S., Aso Y and Kojima S. The effect of irradiation on drug release from poly (lactide) microspheres. *Rad. Phys. Chem.* 46:281 (1995).

259. Volland C.,Wolff M. and Kissel T. The influence of terminal gamma sterilization on captopril containing poly (DL-lactide-co-glycolide) microspheres. *J. Control. Rel.* 31:293 (1994).

260. Pitt C.G., Gratzl M.M., Jeffcoat A.R., Zweidinger R. and Schindler A. Sustained drug delivery systems II, Factors affecting release rates from poly (ϵ caprolactone) and related biodegradable polyesters *J. Pharm. Sci.* 68:1534 (1979).

261. Yamaguchi K and Anderson J.M. In-vivo biocompatibility studies of Medisorb*(R)* 65:35 (DL-lactide/glycolide) copolymer microspheres. *J. Control. Rel.* 24:81 (1993).

262. Cokeman D.L., King R.N. and Andrade J.D. The foreign body reaction : A chronic inflammatory response. *J. Biomed. Mater. Res.* 8:199 (1974).

263. Matlaga B.F. and Salthouse J.M. Ultrastrutural observations of cells at the inferface of a biodegradable polymer : polyglactin 910. *J. Biomed. Mater. Res.* 17:185 (1983).

264. Stinsson N.E. Tissue reaction induced in guinea pigs by particulate polymethacrylate, polyethylene, and nylon of the same size range *Br. J. Exp. Pathol.* 46:135 (1965).

265. Usher F.C. and Wallace S.A. Tissue reaction to plastics : A comparison Nylon, Orlon, Dacron, Teflon and Marlex. *Am. Med. Assoc. Arch. Surg.* 76:997 (1958).

266. Baker H.J., Lindsey J.R. and Weisbroth S.H. *The Laboratory Rat vol.I & II*, Academic press, New York, 1980.

267. Mandl A. M. The phases of the estrus cycle in the adult white rat. *J. Exp. Biol.* 28:576 (1951).

268. Grant K.B. The effects of progesterone and of pentobarbitone adminstered at the dioestrous stage on the ovarian cycle of the rat. *J. Endocr.* 43:539 (1969).

269. Freeman M.E. The neuroendocrine control of the ovarian cycle of the rat. In, Knobil E. and Neil J.D. (eds.), *The Physiology of Reproduction* , 1994, pp. 613-657.

270. Gao Z.H., Shukla A.J., Johnson J.R. and Crowley W.R. Controlled release of contraceptive steroid from biodegradable and injectable gel formulations : in-vivo evaluation. *Pharm. Res.* **12:864 (1995).**